A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus

Exclusion Criteria

• •Contraindications according to the local marketing authorization:
• •1. Participants with eGFR \< 25 mL/min/1.73 m\^2 (calculated based on the CKD-EPI equation, using 2009 formula). eGFR can be reassessed once within 48 hours.
• •2. Participants with severe hepatic impairment (Child-Pugh C).
• •3. Participants with known hypersensitivity to the study treatment (active substance or excipients).
• •4. Participants with Type 1 Diabetes.
• •5. Participants taking concomitant medications that are strong CYP3A4 inhibitors.
• •6. Participants with Addison's disease.
• •Glycated hemoglobin \> 12% (17.5 mmol/L) at the Screening visit.
• •Participants treated with another mineralocorticoid receptor antagonist (MRA), a renin inhibitor, potassium supplements, a potassium sparing diuretic, a potassium binder agent, or angiotensin receptor neprilysin inhibitor (ARNI) within 8 weeks prior to the Screening visit and during finerenone treatment.
• •Participation in another interventional clinical trial within 30 days prior to the Screening visit and during finerenone treatment.
• •Female participants who are pregnant or breast-feeding or plan to become pregnant or to breastfeed during the course of the study.
• •Participants known for lack of compliance with clinic visits or prescribed medication.